Abstract
The Belgian biotech Confo Therapeutics has entered a collaboration with Daiichi Sankyo to develop small-molecule agonists that target G-protein-coupled receptors (GPCRs) to treat central nervous system diseases. Confo will lead the drug discovery efforts, while the Japanese firm has the option under an exclusive global license to develop and commercialize the compounds. Confo technology uses antibodies that can bind to GPCRs to stabilize them, allowing researchers to design ligands that can selectively hitch to the GPCRs when the protein targets are in specific conformations. Confo will receive from Daiichi up-front and potential milestone payments totaling $183 million, as well as royalties.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
